💸 The Tape

The hemp industry has four months left under its current federal definition — and the walls are closing in from every direction at once. Congress set the deadline, but it's the shipping carriers, e-commerce platforms, and state legislatures that are enforcing the ending early.

On November 12, 2026, Section 781 of the appropriations act signed last fall takes full effect, replacing the 2018 Farm Bill's delta-9-only standard with a total THC definition (capturing THCA, Delta-8, and other isomers) and imposing a 0.4 milligram total THC cap per container on finished products. For context, a typical hemp gummy contains 25 mg and a THC seltzer 5-10 mg. The U.S. Hemp Roundtable estimates the new definition eliminates approximately 95% of current hemp-derived products — from a market valued at roughly $28 billion supporting 300,000 jobs and generating $1.5 billion in state tax revenue.

But operators planning to run full speed until November 11 are discovering a harsher reality: the commercial infrastructure is shutting down ahead of the law.

The Carriers Are Already Out

FedEx has taken the most restrictive posture of any major carrier. Its prohibited items list bars cannabis, THC, and marijuana-derived CBD entirely — regardless of state legality — and even federally compliant hemp ingestibles have triggered seizures and account terminations. Unlike UPS, which typically returns non-compliant packages, FedEx will destroy suspect shipments without notice or compensation, and vendors report the highest seizure rate of any carrier. The practical industry consensus has hardened: FedEx is simply not a viable channel for hemp commerce, and most serious operators stopped trying.

USPS still permits compliant hemp shipping under Publication 52 with COA documentation, and UPS operates a gated program requiring dedicated accounts, signed hemp agreements, batch-specific lab results, and adult-signature delivery. But what operators describe as a 2026 "crackdown" is real: stricter shipper vetting, more frequent documentation demands, and faster account terminations after any complaint or inspection exception. Vape products remain entirely banned from direct-to-consumer shipping under the PACT Act across all carriers. And come November 13, most hemp gummies and beverages become non-mailable through every major carrier simultaneously — collapsing the interstate e-commerce model the industry was built on.

The Platforms Are Following

The e-commerce layer is tightening in parallel. Shopify, which has long operated hemp sales under a restrictive attestation framework requiring sellers to certify federal compliance, faces the same November cliff: products exceeding 0.4 mg total THC per container will no longer qualify as federal hemp, and platforms are expected to block those sales entirely rather than absorb the legal exposure of facilitating Schedule I commerce. Industry compliance analysts widely anticipate that Shopify, Square, Stripe, and mainstream payment processors will cut ties with non-compliant hemp merchants well before the deadline — mirroring the de-banking wave that hit CBD in its early days. Operators are already reporting increased documentation demands and merchant account reviews. The message from the commerce stack is unambiguous: the off-ramp is now, not November.

The State Patchwork: Four Markets, Four Realities

Ohio moved first and hardest. Senate Bill 56, signed by Governor Mike DeWine in December 2025, imposed a categorical ban on intoxicating hemp products — one of the most restrictive frameworks in the country, pushing products into dispensary-only channels. The backlash was immediate: a coalition operating as Ohioans for Cannabis Choice launched a signature drive to place a repeal referendum on the November 2026 ballot, and litigation challenging the ban has added a layer of legal uncertainty, with courts and regulators moving in different directions simultaneously.

Virginia took the regulated-middle path early. The commonwealth adopted a total-THC standard with a 2 mg per-package cap under SB 903 back in 2023 — effectively previewing the federal framework years ahead of schedule and gutting its intoxicating hemp retail market. With the state's adult-use retail launch now set for July 1, 2027 under the budget compromise, Virginia's trajectory is clear: cannabinoid commerce is being channeled into the licensed marijuana system, with hemp relegated to genuinely non-intoxicating products.

Florida remains, for now, one of the most permissive major markets — following federal alignment with a mature hemp retail sector spanning smoke shops, gas stations, and dedicated hemp stores. THCA flower and full-strength hemp derivatives remain widely available. But that permissiveness has an expiration date: absent congressional intervention, the November 12 federal redefinition applies in Florida just like everywhere else, and the state's massive hemp retail footprint — which survived multiple legislative ban attempts vetoed or defeated in prior sessions — faces the federal guillotine regardless of Tallahassee's inaction. Potential ballot activity in November adds another variable.

Missouri is the murkiest of the four. The state nominally follows federal alignment despite its recreational marijuana program, but attorney general enforcement actions have pushed THCA and intoxicating hemp into legal gray territory, with retailers facing crackdowns under consumer-protection theories. Meanwhile, HB 2541 — opposed by the U.S. Hemp Roundtable — would reclassify hemp-derived cannabinoids as marijuana under state law, restricting production and sales exclusively to licensed marijuana operators and expelling existing hemp businesses from the market entirely. Missouri illustrates the emerging endgame in adult-use states: fold intoxicating hemp into the licensed cannabis system or eliminate it.

What Comes Next

Two rescue vehicles are circulating in Congress: a proposed two-year delay of the ban and a carve-out for low-dose products — the 5 mg edibles and 10 mg beverages that have gone mainstream at Target and liquor stores. Reports that the Trump administration has engaged Congress about softening the ban have given the industry a flicker of hope, and the beverage category has powerful retail allies. But hope is not a compliance strategy, and nothing has passed.

The rational read for operators: the carriers are enforcing early, the platforms will cut off before the deadline, four state models are converging on dispensary-channel consolidation, and the federal definition changes in four months. The hemp era as the industry has known it ends November 12 — unless Congress acts, the only question left is how orderly the wind-down will be.

The clock isn't just ticking. The infrastructure is already leaving.

📈 Dog Walkers

$CURLF ( ▲ 1.72% ) Plants Flag In Spain

Curaleaf just planted its flag first in Europe's next major medical cannabis market — again.

The company announced that Spain's Agency of Medicines and Medical Devices (AEMPS) has formally approved registration of two standardized cannabis preparations — one THC-dominant, one CBD-dominant — developed by Curaleaf's Spanish manufacturing subsidiary. Based on the official registry numbering (CAN-1 and CAN-2), Curaleaf is the first company to register standardized preparations under Royal Decree 903/2025, Spain's new medical cannabis framework.

The decree, approved in October 2025, established Spain's first clear national pathway for patients to access standardized cannabis preparations through the healthcare system. Curaleaf's registrations clear the way for supply to hospital pharmacies, where the preparations will be used in magistral formulas prepared pursuant to medical prescription.

The first-mover positioning is no accident. Curaleaf has operated an EU-GMP certified facility and R&D laboratory in Alicante for years, and its Medalchemy subsidiary secured the first-ever AEMPS license to process medicinal cannabis derivatives back in May 2020. The company literally built the foundation for this moment over six years.

CEO Boris Jordan called it "a defining moment," noting Spain's nearly 50 million people have always been central to Curaleaf's European vision: "We were the first company to be licensed here in 2020, and we believe we are the first to register under this new framework today."

With Germany's Four 20 Pharma, the UK's Lyphe platform, Portuguese cultivation, and now first-registrant status in Spain, Curaleaf's international moat keeps widening — while most U.S. competitors are still figuring out how to get to Europe at all.

📺 Trade To Black

DEA Rescheduling, SAFE Banking & More | TTB Weekly Recap

• ALJ Hearing Bombshell: One of SAM's own key witnesses acknowledged under cross-examination that cannabis meets the statutory definition for Schedule III — a significant concession as the hearing entered its second week, while the DOJ pushed back against the latest legal effort to halt rescheduling.

• Banking & Ballot Battles: The American Bankers Association renewed its call for Congress to pass SAFE Banking, while Massachusetts officially certified its adult-use repeal initiative for November and Texas lawmakers signaled another hemp THC ban push for the 2027 session.

• Company Milestones: Glass House completed its first international sale (CBD biomass to Europe), Cannara Biotech secured exclusive Canadian rights to Blue River's Ampersand™ live rosin technology, and Vireo Growth announced a market-making agreement to enhance stock liquidity.

• Psychedelics Progress: AtaiBeckley dosed the final patient in its Phase 2b depression trial for VLS-01, with topline data expected in Q4 — joining the wave of late-stage psychedelic readouts arriving before year-end.